Clinical trials: Resectable Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck.
- Trial name
- NCT03341936
- Testing
- Nivolumab, Lirilumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
This phase II trial tests whether atezolizumab works to shrink tumors before surgery in patients with head and neck squamous cell cancer with an unknown or historic primary site that has spread to other places in the lymph nodes…
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT05110781
- Testing
- Atezolizumab, Radiation Therapy, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Davis
Head and Neck Cancer
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00566540
- Testing
- Cisplatin, Paclitaxel, Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
This phase II trial studies how well nivolumab, carboplatin, and paclitaxel work in treating patients with stage III-IV head and neck squamous cell carcinoma that can be removed by surgery.
- Conditions
- Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT03342911
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Head and Neck Cancer, Precancerous Condition
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01084083
- Testing
- cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel
- Where
- 121 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eastern Cooperative Oncology Group
Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2 Regimen in patients with untreated, resectable squamous cell cancer of the head and neck (HNSCC).
- Trial name
- NCT00210470
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Volunteers
- 27 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Head and Neck Neoplasms
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in…
- Trial name
- NCT03765918
- Testing
- Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray
- Where
- 192 sites in United States, Argentina and 22 more
- Volunteers
- 714 people
- Sponsor
- Merck Sharp & Dohme LLC
Resectable Head and Neck Squamous Cell Carcinoma
Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers
The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate…
- Trial name
- HART-HN (NCT05120947)
- Testing
- 42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01898494
- Testing
- Transoral surgery, intensity-modulated radiation therapy, cisplatin
- Where
- 58 sites in United States
- Volunteers
- 519 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cancer of Head and Neck, Head and Neck Cancer
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs)…
- Conditions
- Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- NCT02296684
- Testing
- MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery.
- Conditions
- CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Trial name
- NCT03601507
- Testing
- Alpelisib, Laboratory Biomarker Analysis, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Esophageal Cancer
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00069953
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 97 sites in United States
- Volunteers
- 43 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer, Head and Neck Neoplasms
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Background: Some people who get head and neck cancer will need surgery to treat their cancer. Research suggests that immunotherapy drugs may help fight head and neck cancer if given before surgery.
- Trial name
- NCT04247282
- Testing
- M7824, N803, TriAd vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Oral Squamous Cell Carcinoma
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
The purpose of this study is to investigate the safety and feasibility of neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy in subjects with resectable local advanced oral squamous cell…
- Trial name
- NEOPBOSCC (NCT04649476)
- Testing
- Camrelizumab, Camrelizumanb plus TPF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Hospital of Stomatology, Wuhan University
Neoplasms, Oral, Mouth Neoplasms
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery.
- Trial name
- NCT01553851
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ECHO-07 (NCT00665392)
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 8 sites in France
- Volunteers
- 42 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group